Other examples for immune deviation of DCs in cancer came from rat cancer models demonstrating the presence of DCs expressing low levels of costimulatory molecules that were incapable of inducing T cell activation (Chaux et al., 1997; Bonnotte et al., 2004). Here, CD276 is linked to cancer.